

Genome-wide Association Studies II

BIOS 770

02/17/2025

Jingjing Yang (jingjing.yang@emory.edu)

Outline

- Quality Control
 - Genotype Quality Control
 - Sample Relatedness: Kingship Coefficient
- Population Stratification
 - Genomic Control Factor
 - Genotype Principal Components Analysis
 - Meta-analysis
- Linear Mixed Model (LMM)

GWAS Quality Control

- Filter SNPs
 - Marker genotyping missing rate (e.g., $> 2\%$)
 - Mapping quality for sequence data (based on mapping quality scores)
 - Hardy-Weinberg Equilibrium (HWE) Testing (e.g., p-value $< 10^{-6}$)
 - MAF (e.g., $< 5\%$)
 - Control sample reproducibility
 - Mendelian Errors (e.g., $> 1\%$ families, or > 5 errors) for family-based studies
- Filter samples
 - Sex inconsistencies and chromosomal anomalies
 - Relatedness for population-based studies (how to quantify relatedness given genotype data?)
 - Ethnicity
 - Sample genotyping efficiency/call rate (e.g., $< 98\%$)


Genotype Quality

Data quality is one of the key factors affecting the validity of findings.

Example factors affecting genotype quality:

- Quality of DNA samples, depending on the sample source (e.g., blood, buccal swab, spit kit)
- Handling and storage of the sample (e.g., sample contamination)
- Genotyping platforms/chips
- Sequence errors
- Variant calling

Genotype Quality Control : Sex consistence



Visualization of X and Y probe intensities. The x-axis and y-axis represent the sum of the average over all probes for the normalized Cartesian intensity for allele A and the average over all probes for the normalized Cartesian intensity for allele B using all probes available on the X chromosome and Y chromosome, respectively. The XX (female, red circles) and XY (male, blue triangles) subjects are shown on the bottom right corner and on the top left corner, respectively. The plot reveals two mislabeled individuals (one male with the female cluster, and one female with the male cluster). Several XXY individuals are also clearly visible (upper right corner).

S. Turner et. al. CP hum Genetics. 2011.

<https://doi.org/10.1002/0471142905.hg0119s68>

Kinship QC

- Sample relationship checking
- Pedigree error checking


IBD vs. IBS

Let's ignore disease phenotypes and only consider the similarity of marker alleles.

Identical/Identity by Descent (IBD): Two alleles are IBD if they are the same physical copy.

– E.g., two siblings may inherit the same paternal allele from their father.


Identical/Identity by State (IBS): Two alleles are IBS if they are the same type of allele.



Four alleles in parents ⇒ unambiguous IBD

Type of Relative Pair	Probability of Shared IBD			Expected IBD Sharing
	π_0	π_1	π_2	
Monozygotic twins	0	0	1	2
Full sibs	1/4	1/2	1/4	1
Parent-offspring	0	1	0	1
First cousins	3/4	1/4	0	1/4
Double first cousins	13/16	1/8	1/16	1/4
Grandparent-grandchild, half-sibs, avuncular	1/2	1/2	0	1/2

Sample Relatedness (Z0 and Z1 here are π_0 and π_1)



Points in this plot show pairs of individuals plotted by their degree of relatedness: the proportion of loci where the pair shares one allele IBD (Z1) by the proportion of loci where the pair shares zero alleles IBD (Z0). These values are obtained from PLINK using the `—genome` option. Pairs are color-coded by the type of relationship determined by the pedigree information embedded in the pedfile (also reported by PLINK). This plot omits pairs of individuals having an overall kinship coefficient ≥ 0.05 for clarity. There is a pair of monozygotic twins represented by a point in the lower left at (0,0), because they share two alleles IBD at every locus across the genome.

S. Turner et. al. CP hum Genetics. 2011.

<https://doi.org/10.1002/0471142905.hg0119s68>

Kinship Coefficient ϕ

- ϕ : The probability that two alleles sampled at random from two individuals (one allele per sample) at the same genetic locus are Identical by Descent (IBD).
- $\pi_{0;i,j}, \pi_{1;i,j}, \pi_{2;i,j}$ denote the probability that two individuals (i, j) share 0, 1, and 2 IBD.
- $2\phi_{i,j} = \frac{\pi_{1;i,j}}{2} + \pi_{2;i,j}$

Table 1. Relationship inference criteria based on estimating kinship coefficients (ϕ) and probability of zero IBD sharing (π_0)

Relationship	ϕ	Inference criteria	π_0	Inference criteria
Monozygotic twin	$\frac{1}{2}$	$> \frac{1}{2^{3/2}}$	0	< 0.1
Parent–offspring	$\frac{1}{4}$	$(\frac{1}{2^{5/2}}, \frac{1}{2^{3/2}})$	0	< 0.1
Full sib	$\frac{1}{4}$	$(\frac{1}{2^{5/2}}, \frac{1}{2^{3/2}})$	$\frac{1}{4}$	$(0.1, 0.365)$
2nd Degree	$\frac{1}{8}$	$(\frac{1}{2^{7/2}}, \frac{1}{2^{5/2}})$	$\frac{1}{2}$	$(0.365, 1 - \frac{1}{2^{3/2}})$
3rd Degree	$\frac{1}{16}$	$(\frac{1}{2^{9/2}}, \frac{1}{2^{7/2}})$	$\frac{3}{4}$	$(1 - \frac{1}{2^{3/2}}, 1 - \frac{1}{2^{5/2}})$
Unrelated	0	$< \frac{1}{2^{9/2}}$	1	$> 1 - \frac{1}{2^{5/2}}$

Estimate Kinship Coefficient ϕ by PLINK

- Assume HWE and homogeneous population
- Assume frequency p for reference allele (denoted by A)
- $IBS_{ij}, IBD_{i,j}$ denotes the IBS, IBD between two individuals (i, j)
- Only $IBD_{ij}=0$ can result in $IBS_{ij}=0$, the pair of individuals (i, j) has genotypes AA and aa
- The expected proportion of SNPs with zero IBS can be specified assuming HWE.

$$\Pr(IBS_{ij}=0) = \Pr(AA, aa | IBD_{ij}=0) \cdot \Pr(IBD_{ij}=0) = 2p^2(1-p)^2 \pi_{0ij} \quad (1)$$

This leads to the estimator

$$\hat{\pi}_{0ij} = \frac{\sum_m I_{IBS_{ij}^m=0}}{\sum_m 2\hat{p}_m^2(1-\hat{p}_m)^2} = \frac{N_{AA,aa}}{\sum_m 2\hat{p}_m^2(1-\hat{p}_m)^2}, \quad (2)$$

where $I_{IBS_{ij}^m=0}$ is an indicator of whether the pair of individuals does not share any alleles at the m -th SNP, $N_{AA,aa}$ is the total number of SNPs at which the genotypes of the pair of individuals are different homozygotes, m indexes SNPs excluding those with missing genotypes in either individual of the pair, and allele frequency \hat{p}_m at the m -th SNP is estimated from the genotype frequencies in the entire sample as

$$\hat{p}_m = \frac{\#AA + \#Aa/2}{\#AA + \#Aa + \#aa}. \quad (3)$$

Estimate Kinship Coefficient ϕ by PLINK

- Method of Moments

$$\Pr(IBS_{ij} = k) = \sum_{z=0,1,2} \Pr(IBS_{ij} = k | IBD_{i,j} = z) \pi_{z;i,j}$$

- Estimate $\pi_{1;i,j}, \pi_{2;i,j}$ based on $N_{IBS=1}, N_{IBS=2}, \hat{p}_m, \hat{\pi}_{0;i,j}$. (Purcell et al., 2007.
Tool: PLINK)
- Since the sum of the three IBD statistics is unity, only two IBD statistics are needed to infer the relationship.

$$2\phi_{i,j} = \frac{\pi_{1;i,j}}{2} + \pi_{2;i,j}$$

Estimate Kinship Coefficient ϕ by KING

- Assume HWE and homogeneous population; Assume p_m denotes the frequency of having a reference allele A at a SNP m for both individuals (i, j)
- Genotype score $X^{(i)}$: the number of reference allele for individuals i
- Model genetic distance between a pair of individuals in terms of their kinship coefficient

$$E \left[\left(X^{(i)} - X^{(j)} \right)^2 \right] = 4p(1 - p)(1 - 2\phi_{ij})$$

$$\text{KING-homo estimator: } \widehat{\phi}_{i,j} = \frac{1}{2} - \frac{\sum_m \left(X_m^{(i)} - X_m^{(j)} \right)^2}{4 \sum_m 2\widehat{p}_m(1 - \widehat{p}_m)}$$

- Recall that $2\phi_{i,j} = \frac{\pi_{1;i,j}}{2} + \pi_{2;i,j}$; $\pi_{0;i,j} + \pi_{1;i,j} + \pi_{2;i,j} = 1$; then
$$\widehat{\pi}_1 = 2 - 2\widehat{\pi}_0 - 4\widehat{\phi}_{i,j}; \quad \widehat{\pi}_2 = 4\widehat{\phi}_{i,j} + \widehat{\pi}_0 - 1$$

See derivations in the Supplementary Material of the Bioinformatics paper by A. Manichaikul et. al. 2010. Tool: KING.

Estimate Kinship Coefficient ϕ by KING

$$E(X^{(i)} - X^{(j)})^2 = 4p(1-p)(1-2\phi_{ij}). \quad (4)$$

Let \hat{H}_{ij}/M_{ij} be a consistent estimator of $\sum_m 2p_m(1-p_m)/M_{ij}$ where M_{ij} is the total number of non-missing markers for the pair of individuals. Now, we can estimate the kinship coefficient as

$$\hat{\phi}_{ij} = \frac{1}{2} - \frac{\sum_m (X_m^{(i)} - X_m^{(j)})^2}{4\hat{H}_{ij}}. \quad (5)$$

Note only markers with genotype data for both individuals i and j are used in calculation of $\hat{\phi}_{ij}$. When the sample of individuals is homogeneous, p_m can be estimated by the observed allele frequency \hat{p}_m in (3). The plug-in estimator

$$\hat{H}_{ij}/M_{ij} = \sum_m 2\hat{p}_m(1-\hat{p}_m)/M_{ij} \quad (6)$$

is consistent for $\sum_m 2p_m(1-p_m)/M_{ij}$, and it follows that the estimator $\hat{\phi}_{ij}$ based on (5) and (6) is consistent for ϕ_{ij} . We name the estimating method in Equations (5) and (6) as KING-homo. Together with the IBD estimator (2), all relationships presented in Table 1 can be determined uniquely. Note estimation of π_1 and π_2 can be derived easily according to equations $\hat{\pi}_1 = 2 - 2\hat{\pi}_0 - 4\hat{\phi}$ and $\hat{\pi}_2 = 4\hat{\phi} + \hat{\pi}_0 - 1$.

Estimate Kinship Coefficient ϕ by KING

- Efficient computation matters
- Only SNPs present in both individuals will be used
- An identity is derived (details in the Supplementary Material) to represent the genetic distance between a pair of individuals in terms of their shared genotype counts:

$$(X^{(i)} - X^{(j)})^2 = 4I_{AA,aa} - 2I_{Aa,Aa} + I_{Aa}^{(i)} + I_{Aa}^{(j)}$$

where $I_{Aa}^{(i)}$, $I_{Aa,Aa}$ and $I_{AA,aa}$ indicate whether the i -th individual is heterozygous, whether both individuals are heterozygous, and whether the two individuals have different homozygotes, respectively. Now, we rewrite Equation (5) in terms of genotype counts

$$\hat{\phi}_{ij} = \frac{N_{Aa,Aa} - 2N_{AA,aa}}{2\hat{H}_{ij}} + \frac{1}{2} - \frac{N_{Aa}^{(i)} + N_{Aa}^{(j)}}{4\hat{H}_{ij}} \quad (7)$$

where $N_{Aa,Aa}$, $N_{Aa}^{(i)}$ and $N_{Aa}^{(j)}$ are the total numbers of SNPs at which both individuals of the pair are heterozygous, and the total number of heterozygotes for the i -th and j -th individual, respectively, excluding those SNPs with missing genotypes in either individual of the pair.

$$\hat{H}_{ij} = \sum_m 2\hat{p}_m(1 - \hat{p}_m)$$

Estimate Kinship Coefficient ϕ by KING

- Efficient computation matters
- When each genotype is stored in two bits, Bit Operations (i.e., AND, OR, XOR, NOT) can be used to computing $N_{Aa}^{(i)}$, $N_{Aa}^{(j)}$, $N_{Aa,Aa}$, $N_{AA,aa}$.
Eliminating multiplication and division during the process of scanning the genome.
- $\widehat{H}_{i,j} = \sum_m 2\widehat{p}_m(1 - \widehat{p}_m)$ can be pre-calculated across all SNPs prior to the pair-wise kinship coefficient estimation, and then updating to reflect the set of observed genotypes used in analysis of each pair of individuals.

Efficient computation matters


Table 2. Computation time of two software implementations to estimate kinship coefficients in three sets of GWAS SNP data

Summary of genome scan data				Computing time	
Index	No. of SNPs	No. of samples	No. of pairs	KING	PLINK
1	3 079 857	269	36 046	2 min	2 h 9 min
2	324 748	602	180 901	1 min	1 h 13 min
3	549 338	2 454	3 009 832	25 min	28 h 30 min


The computation time refers to the time to estimate kinship coefficients for all pairs of individuals, excluding overhead costs such as the time to load data into the computer memory. The two KING implementations (the robust algorithm and the algorithm assuming homogeneous samples) took a similar amount of computational time. This computation time can be estimated reliably as the analysis time for the entire data minus the analysis time for only the within-family data. The unit of computation time is in minutes hours. All computation was performed on and Intel Xeon with 3.20 GHz processor.

Fig. 1. Distribution of kinship coefficient estimation.

(A) Distribution of realized IBD-sharing with 150k SNPs (considering sampling one allele per individual);
(B) distribution of kinship coefficient estimates with 150k SNPs;
(C) distribution of kinship coefficient estimates with 5k SNPs;
(D) distribution of kinship coefficient estimates with 500K SNPs.




GWAS Quality Control : Kinship Coefficients 2ϕ



Histogram showing the distribution of pairwise kinship coefficients (where kinship coefficient is greater than 0.05). The peak over 0.5 represents first degree relatives (parent-offspring, full siblings). The peak over 0.25 represents second-degree relatives (half siblings, avuncular, grandparent-grandchild). Third- and fourth-degree relatives begin to blend into more distantly related samples between zero and 0.125.

S. Turner et. al. CP hum Genetics. 2011.

<https://doi.org/10.1002/0471142905.hg0119s68>





Overview of GWAS Quality Control Process

S. Turner et. al. CP hum Genetics. 2011.

<https://doi.org/10.1002/0471142905.hg0119s68>

Check GWAS Results by Quantile-Quantile (QQ) Plot

- Obtained $-\log_{10}(\text{p-values})$ from GWAS
- Sort all $-\log_{10}(\text{p-values})$ from most significant to least
- Pair these with the expected values of order statistics of a $\text{Uniform}(0, 1)$ distribution
- Under NULL hypothesis (no association), p-values follow a $\text{Uniform}(0, 1)$ distribution




Source of Inflated GWAS Results

- Cohorts with samples of different ethnicities: e.g., European, Asian, African ancestries
- The issue of **Population Stratification**

Population Stratification




Population stratification (or population structure) is the presence of a systematic difference in allele frequencies between subpopulations, possibly due to different ancestry.



Allele frequencies at three microsatellite loci (Rosenberg N.A., Hum Biol. 2011). Each of the three loci has exactly eight alleles. In most of the pie charts, one or more alleles is rare or absent.

Causes of population structure

Human migration:



National Geographic


Henn *et al.* (2012) *PNAS*

Inflated False Positives

- Population-based association study methods assume samples are of the same ethnicity.
- The minor allele frequency of SNPs generally vary across different populations
- When the case/control ratio differs across different populations, instead of testing the association between the trait and genotype, you might end up testing the association between the ethnicity and genotype, leading to an inflated number of significant markers.

Example of False Positive Association

Consider genotypes (coded as 00, 01 and 11) at a marker locus



A combined study tends to show association, even though there is no association within each subpopulation.

How to Address Population Stratification?

Most Effective Approach

- Family-based Association Analysis
- Subject to the availability of data



How to Address Population Stratification?

Simplest Approach

- Adjust false positives by **Genomic Control Factor** (not always work)

Check GWAS Results by Quantile-Quantile (QQ) Plot

- Obtained $-\log_{10}(\text{p-values})$ from GWAS
- Sort all $-\log_{10}(\text{p-values})$ from most significant to least
- Pair these with the expected values of order statistics of a $\text{Uniform}(0, 1)$ distribution
- Under NULL hypothesis (no association), p-values follow a $\text{Uniform}(0, 1)$ distribution



Genomic Control Factor

Genomic Control Factor is used to control for systematic inflation of type I error.

The idea is that the statistic T is inflated by an inflation factor λ (i.e., genomic control factor) so that

$$T \sim \lambda \chi_1^2$$

where λ can be estimated by

$$\hat{\lambda} = \text{median}(T_1, T_2, \dots, T_M)/0.456$$

- M is the number of independent tests, though in practice all tests are included.
- The denominator is the median of χ_1^2 distribution.
- $\hat{\lambda}$ should be 1 under H_0 .

Adjust GWAS results by Genomic Control Factor λ_{GC}

- Under null hypothesis (no association signal exists), p-values should follow a uniform distribution within (0, 1)
- Median p-value = 0.5 under null hypothesis, corresponding to chi-square statistic (df=1) value 0.456
- Find the actual median p-value from your GWAS, with corresponding chi-square statistic (df=1) value $\text{median}(T)$

$$\text{Genomic Control Factor: } \lambda_{GC} = \text{median}(T)/0.456$$

- Adjust your GWAS results by λ_{GC}
 - Scale your chi-square statistic test statistics (df=1) by λ_{GC}
 - Recalculate the corresponding GWAS p-values
 - Re-check QQ plot

Limitations of Genomic Control Factor

- Genomic control corrects for stratification by adjusting association statistics at each marker by a uniform overall inflation factor.
- However, some markers differ in their allele frequencies across ancestral populations more than others.
- Thus, the uniform adjustment applied by genomic control may be insufficient at markers having unusually strong differentiation across ancestral populations and may be superfluous at markers devoid of such differentiation, leading to a loss in power

How to Address Population Stratification?

Commonly Used Approach :

- Account for variables representing ethnicity information (**Principal Components Analysis**)


Principal Components Analysis (PCA)

- Consider genotype matrix $X_{n \times p}$, with n individuals and p genome-wide SNPs
- Center and standardize columns in $X_{n \times p} \rightarrow Z_{n \times p}$
- PCA project original genotype data matrix to a new coordinate system such that the PC1 explains the most data variance, and then PC2, ...
 - Calculate a set of loading vectors (w_k , length p , $k=1, 2, \dots$) for PC1, PC2, ...
 - Compute the $n \times n$ variance-covariance matrix for all samples as $\Sigma_{n \times n} = ZZ^T / (n - 1)$
 - Compute the eigenvalue decomposition of Σ , by R function `eigen()`
 - Select top K eigenvectors (w_k) whose corresponding eigenvalues are significantly large (e.g., 5 or 10) by a scree plot
 - Principle components (PCs) are given by: Zw_k

Principal Components Analysis (PCA)


- Principal Components Analysis (PCA) with respect to $X_{n \times p}$
- R function: `prcomp()` ;
<https://www.rdocumentation.org/packages/stats/versions/3.5.1/topics/prcomp>
- PLINK

PCA Visualization



Li et al. Science. 2008; Jakobsson et al. Nature. 2008.

First two principal components among European subjects



Adjust for Top PCs in Regression Model Based Tests

- Adjust for the population structure in your study
- Generally, include PC1-5 as confounding covariates (C) in your regression model
 - $\log \left(\frac{\Pr(Y=1|X)}{\Pr(Y=0|X)} \right) = \beta_0 + \alpha C + \beta_1 X$
 - $Y = \beta_0 + \alpha C + \beta_1 X + \epsilon, \epsilon \sim N(0, \sigma^2)$
- Examine GWAS results by QQ plot for inflated type I error

How to Address Population Stratification?


Most Robust Approach: Stratify Multi-Ethnic Cohorts

- Conduct association studies for samples of the same population/ethnicity
- Combine association results by **Meta-Analysis**
- Subpopulation structure still exist: adjust by PCs


Meta-analysis

- Combine results across multiple studies for the same phenotype
- Improve power for the larger total sample size
- Address between study variances (due to population stratification, study design)
- Avoid the hassle of sharing individual-level genotype/phenotype/covariate data
- It is theoretically shown that the meta-analysis results is equivalent to the joint analysis with individual-level data under ideal situation
 - Same phenotype and covariates
 - No population stratification
 - Balanced case-control study

Improve Power with Larger Total Sample Size



Improve Power with Larger Total Sample Size



Meta-analysis Methods

- Fisher's Method: combining p-values
- Stouffer's Z-score Method
- Inverse-variance method for fixed effect model

Fisher's Method

- Consider the following summary statistics from K studies for testing the association between the same SNP and the same (type) phenotype
 - p-values (p_1, p_2, \dots, p_K)
- Test statistic for meta-analysis
 - $X^2 = -2 \sum_{i=1}^K \log(p_i) \sim \text{Chi-square distribution with df}=2K \text{ under } H_0$
- Why meta test statistic X^2 follows a Chi-square distribution under the NULL hypothesis when there is no association?

Stouffer's Z-score Method

- Consider a series of summary statistics from K studies for testing the association between the same SNP and the same (type) phenotype
 - p-values (p_1, p_2, \dots, p_K)
 - Effect-sizes ($\beta_1, \beta_2, \dots, \beta_K$)
 - Sample sizes (n_1, n_2, \dots, n_K)
- Invert each p-value to a Z-score statistic:
 - $Z_k = \Phi^{-1} \left(1 - \frac{p_k}{2} \right) * \text{sign}(\beta_k)$
 - Φ is the standard normal cumulative density function
- Test statistic (weight by sample sizes) for meta-analysis
 - $Z_{meta} = \frac{\sum_{k=1}^K Z_k w_k}{\sqrt{\sum_{k=1}^K w_k^2}} \sim N(0, 1)$ under H_0
 - $w_k = \sqrt{n_k}$

Inverse-variance method for fixed effect model

- Consider the following summary statistics from K studies for testing the association between the same SNP and the same (type) phenotype
 - Effect-sizes $(\beta_1, \beta_2, \dots, \beta_K)$
 - Variance of effect-sizes (v_1, v_2, \dots, v_K)
- Test statistic (Inverse-variance weighting) for meta-analysis
 - $\beta_{meta} = \frac{\sum_{k=1}^K w_k \beta_k}{\sum_{k=1}^K w_k}, \quad w_k = 1/v_k$
 - $Var(\beta_{meta}) = \frac{1}{\sum_{k=1}^K w_k}$
 - Wald Test Statistic: $\frac{\beta_{meta}}{\sqrt{Var(\beta_{meta})}} \sim N(0, 1)$ under H_0

Table 3 | **Summary of methods for meta-analysis of genome-wide data**

Method	Description	Advantages	Disadvantages	Main software used
<i>P</i> value meta-analysis	Simplest meta-analytical approach	Allows meta-analysis when effects are not available	Direction of effect is not always available; inability to provide effect sizes; difficulties in interpretation	<u>METAL</u> , <u>GWAMA</u> , R packages
Fixed effects	Synthesis of effect sizes. Between-study variance is assumed to be zero	Effects readily available through specialized software	Results may be biased if a large amount of heterogeneity exists	METAL, GWAMA, R packages
Random effects	Synthesis of effect sizes. Assumes that the individual studies estimate different effects	Generalizability of results	Power deserts in discovery efforts; may yield spuriously large summary effect estimates when there are selection biases	GWAMA, R packages
Bayesian approach	Incorporates prior assessment of the genetic effects	Most direct method for interpretation of results as posterior probabilities given the observed data	Methodologically challenging; GWAS-tailored routine software not available; subjective prior information used	R packages
Multivariate approaches	Incorporates the possible correlation between outcomes or genetic variants	Increased power can identify variants that conventional meta-analysis do not reveal using the same data sets	Computationally intensive; software not available for all analyses; some may require individual-level data	GCTA for multi-locus approaches
Other extensions	A set of different approaches that allows for the identification of multiple variants across different diseases	Summary results of previous meta-analyses can be used	May need additional exploratory analyses for the identification of variants; prone to systematic biases	Software developed by the authors of the proposed methodologies

GCTA, genome-wide complex trait analysis; GWAS, genome-wide association study.

Table 1 | **Examples of high-profile consortia for various disease phenotypes**

Consortium (acronym)	Phenotype (or phenotypes)	Publicly available genome-wide data?	Website
AMD	Age-related macular degeneration	Yes, accessible through the website	http://www.sph.umich.edu/csg/abecasis/public/amdgene2012
BCAC	Breast cancer	No	http://ccge.medschl.cam.ac.uk/consortia/bcac
CHARGE	Heart disease and ageing	No	http://web.chargeconsortium.com
GEFOS	Osteoporosis	Yes, accessible through the website	http://www.gefos.org
GIANT	Anthropometric traits	Yes, accessible through the website	http://www.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium
GLGC	TC, HDL-C, LDL-C, triglycerides	Yes, accessible through the website	http://www.sph.umich.edu/csg/abecasis/public/lipids2010
IIBDGC	Inflammatory bowel disease	Yes, accessible through the website	http://www.ibdgenetics.org
IMSGC	Multiple sclerosis	Yes, accessible through the website	https://www.imsgenetics.org/
ISC	Schizophrenia	No	http://pngu.mgh.harvard.edu/isc
MAGIC	Glycaemic traits	Yes, accessible through the website	http://www.magicinvestigators.org
NARAC-III	Rheumatoid arthritis	No	http://www.naracstudy.org/NaracStudy/narac.aspx
TREATOA	Osteoarthritis	Yes, accessible through the website	http://treatoa.eu
WTCCC	Various phenotypes	Yes, accessible through the website	http://www.wtccc.org.uk

HDL-C: high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol.

Evangelou, E. and Ioannidis, J. P.A.
Nature Reviews

Study Design for Meta-analysis




Figure 1 | **Stages in a meta-analysis.** A typical plan for a meta-analysis of genome-wide and next-generation sequence data.

Evangelou, E. and Ioannidis, J. P.A.
Nature Reviews

How to Address Positive Inflation in GWAS?

Effective Approach

- Linear Mixed Model

Linear Mixed Model (LMM)

- Accounts for population stratification and relatedness
- Consider the following standard linear mixed model:

$$\begin{aligned}y_{n \times 1} &= W\alpha + x\beta + Z_{n \times m}u_{m \times 1} + \epsilon \\u_{m \times 1} &\sim MVN_m(0, \lambda\tau^{-1}K) \\ \epsilon &\sim MVN(0, \tau^{-1}I_n)\end{aligned}$$

- $y_{n \times 1}$ denotes the phenotype vector;
- x denotes the genotype vector of the test SNP;
- W denotes the confounding covariates: age, sex, top PCs, etc.;
- $u_{m \times 1}$ denotes the random effect size vector with variance-covariance matrix $\lambda\tau^{-1}K$; taking $m = n, Z = I_n$ for population based GWAS;
 - K is a known $m \times m$ genetic relationship matrix (GRM)
 - I_n is an $n \times n$ identity matrix
- ϵ denotes the error vector with variance-covariance matrix $\tau^{-1}I_n$.

Linear Mixed Model (LMM)

- Efficient statistical inference algorithm used by Genome-wide Efficient Mixed-Model Association (GEMMA) (X. Zhou & M. Stephens, Nature Genetics, 2012).
 - Obtain maximum-likelihood estimates (MLEs)
 - Obtain restricted/residual maximum-likelihood (REML) estimates
 - Calculate exact test statistics

Restricted Maximum Likelihood (REML)

- Accounts for the loss of degrees of freedom due to fixed effects, leading to unbiased variance estimates.
- **Fit a model with fixed effects:** First estimate the fixed effects (α, β) using MLE.
- **Obtain residuals:** Calculate the residuals $(y - W\hat{\alpha} - x\hat{\beta})$.
- **Likelihood of the residuals:** REML maximizes the likelihood of the residuals
- **Maximization:** The REML estimation process maximizes the restricted likelihood function with respect to the variance components — the random effects' covariance matrix $(\lambda\tau^{-1}K)$ and the residual covariance matrix $(\tau^{-1}I)$.

Log-likelihood and Log-REstricted Likelihood Functions

$$l(\lambda, \tau, \boldsymbol{\alpha}, \boldsymbol{\beta}) = \frac{n}{2} \log(\tau) - \frac{n}{2} \log(2\pi) - \frac{1}{2} \log|\mathbf{H}| - \frac{1}{2} \tau (\mathbf{y} - \mathbf{W}\boldsymbol{\alpha} - \mathbf{x}\boldsymbol{\beta})^T \mathbf{H}^{-1} (\mathbf{y} - \mathbf{W}\boldsymbol{\alpha} - \mathbf{x}\boldsymbol{\beta}) \quad (1)$$

and

$$l_r(\lambda, \tau) = \frac{n-c-1}{2} \log(\tau) - \frac{n-c-1}{2} \log(2\pi) + \frac{1}{2} \log|(\mathbf{W}, \mathbf{x})^T (\mathbf{W}, \mathbf{x})| - \frac{1}{2} \log|\mathbf{H}| - \frac{1}{2} \log|(\mathbf{W}, \mathbf{x})^T \mathbf{H}^{-1} (\mathbf{W}, \mathbf{x})| - \frac{1}{2} \tau \mathbf{y}^T \mathbf{P}_x \mathbf{y} \quad (2)$$

where $\mathbf{G} = \mathbf{ZKZ}^T$, $\mathbf{H} = \lambda \mathbf{G} + \mathbf{I}_n$ and $\mathbf{P}_x = \mathbf{H}^{-1} - \mathbf{H}^{-1}(\mathbf{W}, \mathbf{x})((\mathbf{W}, \mathbf{x})^T \mathbf{H}^{-1} (\mathbf{W}, \mathbf{x}))^{-1} (\mathbf{W}, \mathbf{x})^T \mathbf{H}^{-1}$.

- MLE $\hat{\alpha}$, $\hat{\beta}$, and REML $\hat{\tau}$ can be easily obtained if λ is known.
- MLE of $\hat{\alpha}$, $\hat{\beta}$ do not depend on $\hat{\tau}$.
- REML $\hat{\tau}$ is an unbiased estimator for residual variance.

If λ is Known

If λ is known, the log-likelihood is maximized at:

$$\begin{pmatrix} \hat{\alpha} \\ \hat{\beta} \end{pmatrix} = ((\mathbf{W}, \mathbf{x})^T \mathbf{H}^{-1} (\mathbf{W}, \mathbf{x}))^{-1} (\mathbf{W}, \mathbf{x})^T \mathbf{H}^{-1} \mathbf{y},$$
$$\hat{\tau} = \frac{n}{(\mathbf{y} - \mathbf{W}\hat{\alpha} - \mathbf{x}\hat{\beta})^T \mathbf{H}^{-1} (\mathbf{y} - \mathbf{W}\hat{\alpha} - \mathbf{x}\hat{\beta})} = \frac{n}{\mathbf{y}^T \mathbf{P}_x \mathbf{y}}.$$

The last equation uses the property $\mathbf{P}_x \mathbf{H} \mathbf{P}_x = \mathbf{P}_x$. This can be derived by noticing $\mathbf{P}_x = \mathbf{M}_x (\mathbf{M}_x \mathbf{H} \mathbf{M}_x)^{-1} \mathbf{M}_x$, where $\mathbf{M}_x = \mathbf{I}_n - (\mathbf{W}, \mathbf{x}) ((\mathbf{W}, \mathbf{x})^T (\mathbf{W}, \mathbf{x}))^{-1} (\mathbf{W}, \mathbf{x})^T$ and $-$ denotes generalized inverse.

Similarly, the log-restricted likelihood is maximized at

$$\hat{\tau} = \frac{n - c - 1}{\mathbf{y}^T \mathbf{P}_x \mathbf{y}}.$$

Therefore, finding MLE and REML estimates is equivalent to optimizing the following functions with respect to λ :

$$l(\lambda) = \frac{n}{2} \log\left(\frac{n}{2\pi}\right) - \frac{n}{2} - \frac{1}{2} \log |\mathbf{H}| - \frac{n}{2} \log(\mathbf{y}^T \mathbf{P}_x \mathbf{y}),$$
$$l_r(\lambda) = \frac{n - c - 1}{2} \log\left(\frac{n - c - 1}{2\pi}\right) - \frac{n - c - 1}{2} + \frac{1}{2} \log |(\mathbf{W}, \mathbf{x})^T (\mathbf{W}, \mathbf{x})|$$
$$- \frac{1}{2} \log |\mathbf{H}| - \frac{1}{2} \log |(\mathbf{W}, \mathbf{x})^T \mathbf{H}^{-1} (\mathbf{W}, \mathbf{x})| - \frac{n - c - 1}{2} \log(\mathbf{y}^T \mathbf{P}_x \mathbf{y}).$$

Optimizing log-likelihood and log-REstricted likelihood functions with respect to λ

$$l(\lambda) = \frac{n}{2} \log\left(\frac{n}{2\pi}\right) - \frac{n}{2} - \frac{1}{2} \log|\mathbf{H}| - \frac{n}{2} \log(\mathbf{y}^T \mathbf{P}_x \mathbf{y}) \quad (3)$$

$$l_r(\lambda) = \frac{n-c-1}{2} \log\left(\frac{n-c-1}{2\pi}\right) - \frac{n-c-1}{2} + \frac{1}{2} \log|(\mathbf{W}, \mathbf{x})^T (\mathbf{W}, \mathbf{x})| - \frac{1}{2} \log|\mathbf{H}| - \frac{1}{2} \log|(\mathbf{W}, \mathbf{x})^T \mathbf{H}^{-1} (\mathbf{W}, \mathbf{x})| - \frac{n-c-1}{2} \log(\mathbf{y}^T \mathbf{P}_x \mathbf{y}) \quad (4)$$

$$\frac{\partial l(\lambda)}{\partial \lambda} = -\frac{1}{2} \text{trace}(\mathbf{H}^{-1} \mathbf{G}) + \frac{n}{2} \frac{\mathbf{y}^T \mathbf{P}_x \mathbf{G} \mathbf{P}_x \mathbf{y}}{\mathbf{y}^T \mathbf{P}_x \mathbf{y}} \quad (5)$$

$$\frac{\partial^2 l(\lambda)}{\partial \lambda^2} = \frac{1}{2} \text{trace}(\mathbf{H}^{-1} \mathbf{G} \mathbf{H}^{-1} \mathbf{G}) - \frac{n}{2} \frac{2(\mathbf{y}^T \mathbf{P}_x \mathbf{G} \mathbf{P}_x \mathbf{G} \mathbf{P}_x \mathbf{y})(\mathbf{y}^T \mathbf{P}_x \mathbf{y}) - (\mathbf{y}^T \mathbf{P}_x \mathbf{G} \mathbf{P}_x \mathbf{y})^2}{(\mathbf{y}^T \mathbf{P}_x \mathbf{y})^2} \quad (6)$$

Optimizing log-likelihood and log-REstricted likelihood functions with respect to λ

$$\frac{\partial l_r(\lambda)}{\partial \lambda} = -\frac{1}{2} \text{trace}(\mathbf{P}_x \mathbf{G}) + \frac{n-c-1}{2} \frac{\mathbf{y}^T \mathbf{P}_x \mathbf{G} \mathbf{P}_x \mathbf{y}}{\mathbf{y}^T \mathbf{P}_x \mathbf{y}} \quad (7)$$

$$\begin{aligned} \frac{\partial^2 l_r(\lambda)}{\partial \lambda^2} = & \frac{1}{2} \text{trace}(\mathbf{P}_x \mathbf{G} \mathbf{P}_x \mathbf{G}) \\ & - \frac{n-c-1}{2} \frac{2(\mathbf{y}^T \mathbf{P}_x \mathbf{G} \mathbf{P}_x \mathbf{G} \mathbf{P}_x \mathbf{y})(\mathbf{y}^T \mathbf{P}_x \mathbf{y}) - (\mathbf{y}^T \mathbf{P}_x \mathbf{G} \mathbf{P}_x \mathbf{y})^2}{(\mathbf{y}^T \mathbf{P}_x \mathbf{y})^2} \end{aligned} \quad (8)$$

Efficient computation matters

- Use Brent's method to provide an initial value
- Estimate λ by Newton-Raphson's method
- Simplify trace terms and vector-matrix-vector product terms
- Use the recursion properties of the trace terms and vector-matrix-vector product terms

Table 1 Performance of different methods for GWAS with the linear mixed model

Methods			Computing time	
			HDL-C ^b	Crohn's disease ^c
Exact methods	GEMMA	$O(mn^2 + cn^2 + pn^2 + pt_2c^2n)$	33 min	3.3 h
	EMMA	$O(mn^2 + pmn^2 + pt_2n)$	~9 d	~27 years
	FaST-LMM ^d	$O(mn^2 + cn^2 + pn^2 + pt_1c^2n)$	6.8 h	6.2 h
Approximate methods	EMMAX	$O(mn^2 + t_2n + pn^2)$	44 min	6.4 h
	GRAMMAR	$O(mn^2 + t_2n + pn)$	1.6 min	12 min

All computing was performed on a single core of an Intel Xeon L5420 2.50 GHz CPU. The time for the EMMA method is projected from a selection of 10,000 and 100 genetic markers in the HMDP and WTCCC data sets, respectively. Note that EMMA was implemented in R, whereas others were implemented in C. A C implementation of EMMA could be a few times faster. p , the number of genetic markers; n , the number of individuals; m , the number of strains (equal to n for human studies); c , the number of covariates (fixed effects) in addition to the genotypes. t_1 and t_2 are the number of optimization iterations required for Brent's method (super-linear rate of convergence) and the Newton-Raphson method (quadratic rate of convergence), respectively. Note that t_2 is expected to be smaller than t_1 .

^aComplexities are given assuming the usual genome-wide relatedness matrix, which has rank n . In the current implementation of various methods except EMMA, the first terms are actually n^3 , but it would in principle be straightforward to convert them to mn^2 . ^b $m = 99$, $n = 681$, and $p = 1,885,197$. ^c $m = n = 4,686$, and $p = 442,001$. ^dThese results are for the algorithm in FaST-LMM that uses the standard full-rank relatedness matrix, which produces P values that are identical to those generated in GEMMA and EMMA.

Test Statistics and P-values

To test the null hypothesis $\beta = 0$, we obtain the likelihood ratio test statistic with MLE estimates and the Wald test statistic with the REML estimate as suggested^{2,1}:


$$D_{lrt} = 2 \log \frac{l_1(\hat{\lambda}_1)}{l_0(\hat{\lambda}_0)},$$
$$F_{Wald} = \frac{\hat{\beta}^2}{V(\hat{\beta})}.$$

where l_1 and l_0 are the likelihood functions for the null and the alternative models, respectively; $\hat{\lambda}_0$ and $\hat{\lambda}_1$ are the MLE estimates for the null and the alternative models, respectively; $\hat{\beta} = (\mathbf{x}^T \mathbf{P}_c(\hat{\lambda}_r) \mathbf{x})^{-1} (\mathbf{x}^T \mathbf{P}_c(\hat{\lambda}_r) \mathbf{y})$ is the estimate for β obtained using the REML estimate $\hat{\lambda}_r$ in the alternative model; and $V(\hat{\beta}) = (n - c - 1)^{-1} (\mathbf{x}^T \mathbf{P}_c(\hat{\lambda}_r) \mathbf{x})^{-1} (\mathbf{y}^T \mathbf{P}_x(\hat{\lambda}_r) \mathbf{y})$ is the variance for $\hat{\beta}$. Under the null hypothesis the likelihood ratio test statistic D_{lrt} and the Wald test statistics F_{Wald} come from a $\chi^2(1)$ and a $F(1, n - c - 1)$ distribution respectively, and p values can be calculated accordingly.

GEMMA
help
control for
false
positives in
differential
gene
expression
studies.

[Tang S. et.
al.
Scientific
Reports,
2023.](#)

From: [Differential gene expression analysis based on linear mixed model corrects false positive inflation for studying quantitative traits](#)



QQ-plots and genomic control factors of DGE results by LMM (A–D) and standard linear regression model (E–H) with the discovery RNA-Seq data of DLPFC tissue of cognitive decline and three AD-NC traits.

Available Tools

- PLINK : QC, PCA of genotype data, GWAS
<https://www.cog-genomics.org/plink/>
- KING : Relationship inference
<https://www.kingrelatedness.com/manual.shtml>
- METAL : Meta-analysis tool
https://genome.sph.umich.edu/wiki/METAL_Documentation
- GEMMA: GWAS and SNP heritability estimation by LMM, BVSR
<https://github.com/genetics-statistics/GEMMA>

Topics for Next Lecture

- Fine-map GWAS Results
 - Conditional Analysis
 - Bayesian Method: FINEMAP
 - Based on the “Sum of Single Effects” model: SuSiE
- Bayesian Functional GWAS